Altimmune (DE:3G0)
NASDAQ:3G0
3G0 Stock Chart & Stats
€2.95
€0.20(2.91%)
At close: 4:00 PM EST
€2.95
€0.20(2.91%)
Day’s Range― - ―
52-Week Range€2.20 - €5.32
Previous CloseN/A
Volume5.10K
Average Volume (3M)171.00
Market Cap
€481.35M
Enterprise Value€171.25M
Total Cash (Recent Filing)€331.54M
Total Debt (Recent Filing)€35.85M
Price to Earnings (P/E)―
Beta0.87
Next Earnings
Aug 06, 2026EPS Estimate
-0.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.93
Shares Outstanding194,474,150
10 Day Avg. Volume85
30 Day Avg. Volume171
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)1.41
Price to Sales (P/S)7757.46
P/FCF Ratio-4.71
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€11.16Price Target Upside278.44% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
EPS Forecast (FY)-0.6
Revenue Forecast (FY)€6.13K
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthA debt-free balance sheet with meaningful equity and assets provides durable financial flexibility for a clinical-stage biotech. It lowers refinancing urgency, supports multi-year clinical programs, and improves ability to absorb clinical setbacks without immediate solvency pressure.
Substantial Pro‑forma Cash RunwayA large, recent financing that produces pro‑forma cash runway materially reduces execution risk for planned Phase III activities. It enables uninterrupted trial start‑up, site activation and CMC preparation over several years, improving probability of reaching registrational milestones.
Regulatory Recognition & Phase III AlignmentBreakthrough Therapy designation and regulatory alignment on a global Phase III protocol increase informational efficiency with regulators and can accelerate review pathways. This structural endorsement raises the odds of favorable regulatory interactions and partnership interest.
Bears Say
High Cash BurnSustained negative operating and free cash flow requires ongoing capital access or spending reductions. Even with current runway, persistent burn elevates dilution risk over the medium term and forces prioritization decisions that can delay or narrow development programs.
Minimal Revenue; Large Net LossesPractically no commercial revenue and deep net losses mean the business is entirely dependent on financing and milestones. This structural lack of diversified cash flow amplifies execution and financing risk until a product achieves market authorization and sustainable sales.
Long, Complex Registrational ProgramA lengthy, biopsy‑based Phase III with limited interim readouts extends time to approval and revenue, increasing exposure to competitive entrants and operational execution risk (site activation, pathology comparability). This structural timeline compresses optionality and lengthens capital dependency.
Altimmune News
3G0 FAQ
What was Altimmune’s price range in the past 12 months?
Altimmune lowest stock price was €2.20 and its highest was €5.32 in the past 12 months.
What is Altimmune’s market cap?
Altimmune’s market cap is €481.35M.
When is Altimmune’s upcoming earnings report date?
Altimmune’s upcoming earnings report date is Aug 06, 2026 which is in 39 days.
How were Altimmune’s earnings last quarter?
Altimmune released its earnings results on May 13, 2026. The company reported -€0.157 earnings per share for the quarter, beating the consensus estimate of -€0.211 by €0.054.
Is Altimmune overvalued?
According to Wall Street analysts Altimmune’s price is currently Undervalued.
Does Altimmune pay dividends?
Altimmune does not currently pay dividends.
What is Altimmune’s EPS estimate?
Altimmune’s EPS estimate is -0.13.
How many shares outstanding does Altimmune have?
Altimmune has 194,474,150 shares outstanding.
What happened to Altimmune’s price movement after its last earnings report?
Altimmune reported an EPS of -€0.157 in its last earnings report, beating expectations of -€0.211. Following the earnings report the stock price went up 0.195%.
Which hedge fund is a major shareholder of Altimmune?
Currently, no hedge funds are holding shares in DE:3G0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Altimmune Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€11.16 (278.44% Upside)
€11.16 (278.44% Upside)
Blogger Sentiment
Bullish
DE:3G0 Sentiment 70%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth €96.1K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-21.88%
12-Months-Change
Fundamentals
Return on Equity
-42.57%
Trailing 12-Months
Asset Growth
113.42%
Trailing 12-Months
Company Description
Altimmune
Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for obesity and various liver diseases. Its primary investigational drug, pemvidutide (proposed INN, previously known as ALT-801), operates as a GLP-1/glucagon dual receptor agonist. This compound is currently undergoing Phase 1b clinical trials, exploring its efficacy in treating both obesity and non-alcoholic steatohepatitis (NASH). Additionally, Altimmune is advancing HepTcell, an immunotherapeutic candidate, through Phase 2 clinical trials. This therapy is designed for individuals suffering from chronic hepatitis B virus infection. The enterprise, initially named Vaxin Inc., officially adopted the Altimmune, Inc. moniker in September 2015. Established in 1997, the company maintains its corporate headquarters in Gaithersburg, Maryland.
3G0 Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed significant progress: strong financing ($225M offering; $535M pro forma cash), regulatory recognition (Breakthrough Therapy), alignment with FDA/EMA on the PERFORMA Phase III protocol, robust Phase II efficacy/tolerability signals, and near-term readouts (AUD topline; RESTORE enrollment). Challenges were mostly operational and expected for a late-stage biotech: higher G&A and R&D as programs advance, a wider net loss in the quarter, ongoing validation/integration of digital pathology tools, and a competitive landscape necessitating clear differentiation. Overall, the positives — especially the cash runway and Phase III readiness — materially outweigh the manageable execution and competitive risks.View all DE:3G0 earnings summaries3G0 Stock 12 Month Forecast
Average Price Target
€11.16
▲(278.44% Upside)
Technical Analysis
Tvardi Therapeutics
―
Diamedica Therapeutics
―
Alpha Tau Medical Ltd
―
enGene Holdings
―
Lexeo Therapeutics, Inc.
―
Options Prices
Currently, No data available
---